The Europe Cord Blood Banking Services Market should witness market growth of 12.4% CAGR during the forecast period (2022-2028).
Banking of cord blood is absolutely optional. Some parents decide to save their baby's cord blood, while others do not. The cord blood from the newborn is discarded with the placenta if parents don't donate it or keep it in storage. Parents who choose to store their baby's placental and umbilical cord blood in order to support their child's potential future medical requirements have the option of cord blood banking. It can also be applied to other biologically related kids, whether they are members of their own family or not.
The practice of cord blood banking has various advantages. However, the way one go about it will depend on a number of things, such as the medical requirements of the family and financial circumstances. The cord blood of a newborn can almost always be donated to a public bank. This could benefit a lot of people.
Private cord banking may be the best option if someone have a family member who might need the cord blood bank to address a medical issue, even though the majority of medical institutions do not advise it. In either case, it's a wise idea to see a medical expert before selecting whether or not to bank the newborn's cord blood.
The UK Stem Cell Strategic Forum report's recommendations will be put into practice with the assistance of a number of millions from the government, which is committed to enhancing UK stem cell services. The government is working to establish a cord blood bank with 50,000 units, and this goal is required to be met with a cost-effective and strategic approach. Also, a growing percentage of solid organ transplant recipients are surviving on long-term immunosuppression and exhibiting post-transplant lymphoproliferative diseases is posing pressure over the government to establish better healthcare services for cord blood banking. This supports the market growth in cord blood banking services in the Europe region.
The Germany market dominated the Europe Cord Blood Banking Services Market by Country in 2021; thereby, achieving a market value of $190.8 million by 2028. The UK market is exhibiting a CAGR of 11.5% during (2022-2028). Additionally, The France market would experience a CAGR of 13.2% during (2022-2028).
Based on Component, the market is segmented into Cord Tissue and Cord Blood. Based on Storage Services, the market is segmented into Private Cord Blood Banks and Public Cord Blood Banks. Based on Application, the market is segmented into Diabetes, Cancer Disease, Blood Disease, Immune Disorders, Metabolic Disorders, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AMAG Pharmaceuticals, Inc., Americord Registry LLC, StemCyte, Inc., Cordlife Group Limited, cordvida, Cryo-Cell International, Inc., CryoHoldco de LatinoAmérica and Vita 34 AG
Banking of cord blood is absolutely optional. Some parents decide to save their baby's cord blood, while others do not. The cord blood from the newborn is discarded with the placenta if parents don't donate it or keep it in storage. Parents who choose to store their baby's placental and umbilical cord blood in order to support their child's potential future medical requirements have the option of cord blood banking. It can also be applied to other biologically related kids, whether they are members of their own family or not.
The practice of cord blood banking has various advantages. However, the way one go about it will depend on a number of things, such as the medical requirements of the family and financial circumstances. The cord blood of a newborn can almost always be donated to a public bank. This could benefit a lot of people.
Private cord banking may be the best option if someone have a family member who might need the cord blood bank to address a medical issue, even though the majority of medical institutions do not advise it. In either case, it's a wise idea to see a medical expert before selecting whether or not to bank the newborn's cord blood.
The UK Stem Cell Strategic Forum report's recommendations will be put into practice with the assistance of a number of millions from the government, which is committed to enhancing UK stem cell services. The government is working to establish a cord blood bank with 50,000 units, and this goal is required to be met with a cost-effective and strategic approach. Also, a growing percentage of solid organ transplant recipients are surviving on long-term immunosuppression and exhibiting post-transplant lymphoproliferative diseases is posing pressure over the government to establish better healthcare services for cord blood banking. This supports the market growth in cord blood banking services in the Europe region.
The Germany market dominated the Europe Cord Blood Banking Services Market by Country in 2021; thereby, achieving a market value of $190.8 million by 2028. The UK market is exhibiting a CAGR of 11.5% during (2022-2028). Additionally, The France market would experience a CAGR of 13.2% during (2022-2028).
Based on Component, the market is segmented into Cord Tissue and Cord Blood. Based on Storage Services, the market is segmented into Private Cord Blood Banks and Public Cord Blood Banks. Based on Application, the market is segmented into Diabetes, Cancer Disease, Blood Disease, Immune Disorders, Metabolic Disorders, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AMAG Pharmaceuticals, Inc., Americord Registry LLC, StemCyte, Inc., Cordlife Group Limited, cordvida, Cryo-Cell International, Inc., CryoHoldco de LatinoAmérica and Vita 34 AG
Scope of the Study
By Component
- Cord Tissue
- Cord Blood
By Storage Services
- Private Cord Blood Banks
- Public Cord Blood Banks
By Application
- Diabetes
- Cancer Disease
- Blood Disease
- Immune Disorders
- Metabolic Disorders
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- AMAG Pharmaceuticals, Inc.
- Americord Registry LLC
- StemCyte, Inc.
- Cordlife Group Limited
- cordvida
- Cryo-Cell International, Inc.
- CryoHoldco de LatinoAmérica
- Vita 34 AG
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Europe Cord Blood Banking Services Market by Component
Chapter 4. Europe Cord Blood Banking Services Market by Storage Services
Chapter 5. Europe Cord Blood Banking Services Market by Application
Chapter 6. Europe Cord Blood Banking Services Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- AMAG Pharmaceuticals, Inc.
- Americord Registry LLC
- StemCyte, Inc.
- Cordlife Group Limited
- cordvida
- Cryo-Cell International, Inc.
- CryoHoldco de LatinoAmérica
- Vita 34 AG
Methodology
LOADING...
